Bone Biologics Corp (BBLG)

• $1.13

  $1.28

  $1.19
  

  5.04%

  Downside

  Day's Volatility :11.9%

  Upside

  7.22%

  
• $0.53

  $10.56

  $1.19
  

  55.46%

  Downside

  52 Weeks Volatility :94.98%

  Upside

  88.73%

  

Returns

What analysts predicted

Upside of 1307.56%

• Tower Research Capital LLC

  0.24%

• UBS Group AG

  0.03%

• McMahon Financial Advisors, LLC

  0.02%

a publicly-held biotechnology company that is a spin off of the musculoskeletal transplant foundation (mtf) using technology discovered and licensed from ucla. bone biologics market and focus is in the regenerative medicine orthobiologics space. bone biologics was founded in 2004 by university of california professors in collaboration with an osaka university professor and a usc surgeon and acquired in 2006 by mtf as the major shareholder, who has been the primary funder since the acquisition. the company’s proprietary, patented platform technology ucb-1™, exclusively licensed from ucla, has met and surpassed existing standards of care outcomes in completed large animal model (sheep and rhesus monkey) studies that have demonstrated that the ucb-1™ technology facilitates superior normal bone growth. the company believes that as a platform technology, ucb-1™ has broad applications in delivering improved outcomes in almost all surgical procedures involved in bone repair and regeneration.